Through this mechanism, lenalidomide, pomalidomide, and mezigdomide in combination with a bromodomain-containing protein 4 (BRD4) inhibitor resulted in synergistic decreases in MM cell proliferation and increases in apoptosis [72], suggesting the potential for mezigdomide to have specific activity in MM with gain/amplification of 1q21 via mediation of proteasomal degradation of CKS1B. Here, BRD4 is linked to Miyoshi myopathy.